Pharvaris’ (PHVS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Pharvaris (NASDAQ:PHVS) in a report issued on Tuesday, Marketbeat.com reports. They currently have a $60.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on PHVS. New Street Research set a $60.00 target price on Pharvaris in a report on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Friday, July 17th. HSBC upgraded Pharvaris to an “overweight” rating in a research report on Thursday, August 13th. Citizens Jmp lifted their target price on Pharvaris from $74.00 to $75.00 and gave the company a “market outperform” rating in a research report on Thursday, August 13th. Finally, Wedbush reissued an “outperform” rating and set a $42.00 target price on shares of Pharvaris in a research note on Tuesday. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Pharvaris has a consensus rating of “Moderate Buy” and an average price target of $59.50.

Pharvaris Stock Down 0.6%

Shares of Pharvaris stock opened at $37.51 on Tuesday. Pharvaris has a 12-month low of $20.65 and a 12-month high of $43.25. The company has a market capitalization of $2.45 billion, a price-to-earnings ratio of -12.30 and a beta of -2.33. The firm’s 50-day moving average price is $35.01 and its two-hundred day moving average price is $31.34.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). On average, sell-side analysts expect that Pharvaris will post -3.1 earnings per share for the current year.

Insider Transactions at Pharvaris

In other Pharvaris news, insider Anne Lesage sold 30,703 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47. Following the completion of the transaction, the insider owned 93,969 shares of the company’s stock, valued at $3,334,959.81. This represents a 24.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88. Following the completion of the transaction, the director directly owned 315,167 shares of the company’s stock, valued at approximately $11,185,276.83. The trade was a 8.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 133,655 shares of company stock valued at $4,798,202 over the last quarter. 11.84% of the stock is currently owned by insiders.

Institutional Trading of Pharvaris

A number of hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Pharvaris by 41.1% in the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after buying an additional 15,769 shares during the period. JPMorgan Chase & Co. boosted its position in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the period. Legal & General Group Plc grew its holdings in Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares during the last quarter. Amundi grew its holdings in Pharvaris by 2,741,600.0% during the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after acquiring an additional 27,416 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in Pharvaris by 19.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after acquiring an additional 7,879 shares during the last quarter.

Trending Headlines about Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Analysts continued to support Pharvaris after positive Phase 3 data for extended-release deucrictibant in the CHAPTER-3 prophylaxis trial. The drug met its primary and secondary efficacy endpoints, strengthening the case for regulatory filings expected to begin in the first half of 2027.
• Positive Sentiment: RBC Capital reaffirmed its Buy/Outperform view and raised its price target to $62 from $52, citing the potential for deucrictibant XR to capture share in the hereditary angioedema market. RBC Capital rating
• Positive Sentiment: Citizens JMP increased its target to $79 from $75 and maintained a Market Outperform rating. HC Wainwright reiterated Buy with a $60 target, while Wedbush maintained Outperform. These actions reflect growing analyst confidence following Pharvaris’ Phase 3 progress.
• Positive Sentiment: Commentary highlighted Pharvaris’ potential to offer oral therapies for both on-demand treatment and prevention of hereditary angioedema attacks, which could improve its competitive positioning. Pharvaris HAE market opportunity
• Neutral Sentiment: The bullish outlook remains dependent on regulatory approval, successful commercialization and competition in the HAE market. Pharvaris is still a clinical-stage biotechnology company, and RBC continues to classify the stock as speculative.
• Negative Sentiment: President Peng Lu sold 15,000 shares for approximately $610,200, reducing his direct ownership by 18.71%. The sale may create a modest sentiment overhang, although it does not alter the company’s clinical results.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.